Zymeworks Inc. (ZYME) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. This is the conference operator. Welcome to DesignWorks' fourth quarter 2025 results conference call and webcast. As a reminder, all participants are in listen-only mode, and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. I would now like to turn the conference over to Shernell Elmander, Vice President of Investor Relations. Shernell, please go ahead. Thank you, operator, and good morning, everyone. Thank you for joining our fourth quarter 2025 results conference call. As usual, I'd like to remind you that we'll be making a number of forward-looking statements during this call, including without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary. Forward-looking statements are based upon our current expectations and various assumptions and are subject to the risks and uncertainties, including those associated with the companies in our industry and at our stage of development. The discussion of these risks and uncertainties I refer you to the latest SEC findings as found on our website and as filed with the SEC. In a moment, I'll hand over the call to Ken Galbraith, our Chair, CEO, and Interim Chief Financial Officer, who will provide an overview of recent business updates. Ken will then hand the call over to Bijal Desai, our Senior VP of Finance, to discuss our cash position and financial results for the fourth quarter of 2025. Following this, Dr. Sabine Mikan, our SVP and Chief Medical Officer, We provide progress updates on the Phase 1 clinical trial for 251. At the end of the call, Ken, Sabine, and Bijal will be joined for Q&A by Paul Moore, our Chief Scientific Officer, Scott Pashtun, our Acting Chief Investment Officer, and...